Onco-Innovations Limited is advancing its cancer drug discovery efforts through a new pilot collaboration with Kuano Ltd., a next-generation biotechnology company leveraging quantum mechanics and artificial intelligence. The initiative aims to accelerate the development of Onco-Innovations’ PNKP Inhibitor Technology, specifically the compound A83B4C63, which targets a key enzyme involved in DNA repair and shows promise in treating solid tumors. Under the pilot project, Kuano will deploy its quantum-ready analytics platform to provide deep structural insights into how A83B4C63 interacts with PNKP. Using quantum-level molecular modeling, Kuano’s technology will analyze binding poses, conformational changes, and the precise mechanism of inhibition. These detailed simulations are expected to guide the optimization of compound design, enhance selectivity and potency, and support the rapid progression of candidates into preclinical validation. The collaboration integrates Kuano’s quantum-enabled computational capabilities with Onco-Innovations’ existing AI-driven drug discovery infrastructure. This combined approach is designed to streamline the path from theoretical modeling to experimental synthesis and testing, significantly reducing development timelines. The pilot, scheduled to run through the fourth quarter of 2025, will deliver validated structural models, mechanistic hypotheses, and data to inform future initiatives. These include quantum-ready QSAR modeling, toxicity prediction, and generative compound design across the broader PNKP inhibitor pipeline. Vid Stojevic, CEO and Co-Founder of Kuano, expressed enthusiasm for the partnership, stating that applying quantum precision to challenging oncology targets like PNKP could unlock new therapeutic possibilities and accelerate the creation of next-generation drugs. Thomas O'Shaughnessy, CEO of Onco-Innovations, emphasized the strategic importance of the collaboration, noting it reflects the company’s commitment to leading in oncology innovation by combining advanced computational science with experimental research. He highlighted that this pilot is a critical step toward realizing the full potential of their PNKP inhibitor platform. Onco-Innovations, a Canadian-based company focused on pioneering cancer treatments, holds an exclusive worldwide license to patented technology targeting solid tumors. The company continues to expand its pipeline through strategic partnerships and cutting-edge scientific approaches. This news release contains forward-looking statements regarding expected benefits of the collaboration, the potential of the PNKP inhibitor technology, and future development plans. These statements involve risks and uncertainties, and actual results may differ materially due to factors beyond the company’s control. Readers are cautioned not to place undue reliance on these forward-looking statements, which are based on current assumptions and are subject to change.